Social Determinants of Health Shape Outcomes in C difficile Infections
December 4th 2024Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses a study she conducted that highlights how social determinants of health exacerbate severity and increase rates of mortality from Clostridioides difficile infections in vulnerable communities.
Read More
FDA Receives 2 Supplemental Biologics License Applications for Guselkumab for Pediatric Indications
December 3rd 2024If approved, the new indications include children 6 years and older with moderate to severe plaque psoriasis and children 5 years and older with active juvenile psoriatic arthritis.
Read More
Precision Oncology: Expanding Therapeutic Horizons With Trastuzumab Deruxtecan
December 3rd 2024The tumor-agnostic FDA approval of T-DXd for HER2-positive unresectable or metastatic solid malignancies exemplifies the importance of understanding the risks associated with targeted therapy and the need for proactive monitoring strategies.
Read More
Data Further Confirm Proposed Denosumab Biosimilar Shows Similar Efficacy to Originator
December 2nd 2024Investigators presented additional data from a clinical trial at the American College of Rheumatology Convergence, demonstrating similar safety for postmenopausal women with osteoporosis.
Read More
Childhood Pneumococcal Vaccination Programs Indirectly Protect Adults From Pneumococcal Disease
November 29th 2024Pneumococcal disease incidence decreased in adults after pneumococcal vaccines began to be used in children due to indirect protection, with fewer adults found to carry the bacterium that causes disease.
Read More